ReviewCancers2022
Genetic Landscape of Multistep Hepatocarcinogenesis.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- IRF8 Suppresses Hepatocellular Carcinoma Progression Through LIAS-Dependent IFN Production and Cuproptosis Activation.Genes, chromosomes & cancer · 2026Article
- Compatibility mechanism ofChinese herbal medicines · 2026Article
- Therapeutic potential of natural triterpenoids in liver cancer.Medical oncology (Northwood, London, England) · 2025Review
- PRC1, CDCA3, and CDC20 are upregulated and Treg numbers are decreased in canine massive hepatocellular carcinoma.BMC veterinary research · 2025Article
- Review
- Improving diagnostic accuracy in cirrhotic patients: a comprehensive multicenter analysis of contrast-enhanced ultrasound-guided biopsy in a large cohort of 2056 patients.La Radiologia medica · 2025Article
- Mint3 as a Molecular Target Activated in the Early Stage of Hepatocarcinogenesis.International journal of molecular sciences · 2025Article
- BRG1 promotes liver cancer cell proliferation and metastasis by enhancing mitochondrial function and ATP5A1 synthesis through TOMM40.Cancer biology & therapy · 2024Article
- Advanced Imaging of Hepatocellular Carcinoma: A Review of Current and Novel Techniques.Journal of gastrointestinal cancer · 2024Review
- Article
- Single cell-spatial transcriptomics and bulk multi-omics analysis of heterogeneity and ecosystems in hepatocellular carcinoma.NPJ precision oncology · 2024Article
- Whole genome and RNA sequencing analyses for 254 Taiwanese hepatocellular carcinomas.Biomarker research · 2023Article
- Hepatocellular Carcinoma Gene Expression:iLIVER · 2023Review
- Imaging Diagnosis of Hepatocellular Carcinoma: A State-of-the-Art Review.Diagnostics (Basel, Switzerland) · 2023Review
- Interplay Between Fatty Acids, Stearoyl-Co-A Desaturase, Mechanistic Target of Rapamycin, and Yes-Associated Protein/Transcriptional Coactivator With PDZ-Binding Motif in Promoting Hepatocellular Carcinoma.Gastro hep advances · 2023Review
- Clinical and Molecular Basis of Hepatocellular Carcinoma after Hepatitis C Virus Eradication.Pathogens (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is a major cause of cancer-related death worldwide. Although several targeted therapy agents are available for advanced HCC, their antitumor efficacy remains limited. As the complex genetic landscape of HCC would compromise the antitumor efficacy of targeted therapy, a deeper understanding of the genetic landscape of hepatocarcinogenesis is necessary. Recent comprehensive genetic analyses have revealed the driver genes of HCC, which accumulate during the multistage process of hepatocarcinogenesis, facilitating HCC genetic heterogeneity. In addition, as early genetic changes may represent key therapeutic targets, the genetic landscapes of early HCC and precancerous liver tissues have been characterized in recent years, in parallel with the advancement of next-generation sequencing analysis. In this review article, we first summarize the landscape of the liver cancer genome and its intratumor heterogeneity. We then introduce recent insight on early genetic alterations in hepatocarcinogenesis, especially those in early HCC and noncancerous liver tissues. Finally, we summarize the multistep accumulation of genetic aberrations throughout cancer progression and discuss the future perspective towards the clinical application of this genetic information.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.